Blood cancers, anaemias, haemophilia and other blood disorders share some commonalities when it comes to market access. Among others, these diseases:

·     require a mix of inpatient and outpatient patient management that has an impact on market access requirements and pathways;

·     patients are often subject to bone marrow and stem cell transplants with the connected high risks and costs;

·     some of these diseases are genetic or can affect relatively young patients;

·     new technologies like cell and gene therapies promise a cure for some of these patients.

At forethought access, we support our customers with front line knowledge of market access pathways, decision makers and drivers combined with a general understanding of scientific and clinical peculiarities of these diseases and their treatments.